Impact of the updated 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) gene testing in invasive breast cancers: A single center study-Reference-Cited by-同舟云学术

Impact of the updated 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) gene testing in invasive breast cancers: A single center study

Published:2022-06 Issue: Volume:58 Page:151935
ISSN:1092-9134
Container-title:Annals of Diagnostic Pathology
language:en
Short-container-title:Annals of Diagnostic Pathology

Author:

Lim Tse Hui,Lim Alvin Soon Tiong,Tien Sim Leng,Tan Puay Hoon

Publisher

Elsevier BV

Subject

General Medicine,Pathology and Forensic Medicine

Reference26 articles.

1. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

2. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine;Ross;Oncologist,2009

3. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer;Vogel;J Clin Oncol,2002

4. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial;Hurvitz;Lancet Oncol,2018

5. Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. POTENTIAL IMPACT OF HERCEPTEST™ MAB PHARMDX (DAKO OMNIS) (GE001) IN BREAST CANCER DIAGNOSIS;Polish Journal of Pathology;2023